Posts by Adam Scott Feldman, MD, MPH
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
Massachusetts General Hospital researchers recommend patients who have a prostate lesion on multiparametric MRI should undergo both standard and targeted biopsy using the transperineal approach, as that resulted in a Gleason grade most concordant with the results from radical prostatectomy specimens.
Review: Active Surveillance for Intermediate-risk Prostate Cancer
Madhur Nayan, MDCM, PhD, Filipe L. F. Carvalho, MD, PhD, and Adam S. Feldman, MD, MPH, recently published a narrative review that discusses variations in the definitions of intermediate-risk prostate cancer and the scant evidence about when it can be managed with active surveillance.
Combination Prostate Biopsy Can Overestimate Gleason Grade Compared with Surgical Pathology
By studying men who underwent both standard prostate biopsy and MRI–ultrasound targeted biopsy, Adam S. Feldman, MD, MPH, of the Department of Urology, and colleagues determined combination biopsy can overestimate Gleason grade compared to surgical pathology, presenting a risk of overtreatment.
Using Machine Learning to Predict Prostate Cancer Progression During Active Surveillance
Madhur Nayan, MDCM, PhD, and Adam S. Feldman, MD, MPH, and colleagues created the first machine learning models for predicting prostate cancer progression during active surveillance and found they outperformed traditional logistic regression.
Mass General Offers Novel, Kidney-saving Urothelial Cancer Treatment
Mitomycin chemoablation with a mitomycin gel, a novel treatment offered in the Department of Urology at Massachusetts General Hospital, can avoid the need for surgical removal of the kidney and ureter in patients with upper tract urothelial cancer.
Considerations in Selecting Patients for Trimodal Therapy for Muscle-invasive Bladder Cancer
Adam S. Feldman, MD, MPH, and colleagues review the patient-related and tumor-related factors that should most strongly influence the decision between trimodal therapy and radical cystectomy for patients with muscle-invasive bladder cancer.
New Research Indicates Promising Future for Prostate Cancer Diagnosis
Research conducted by Dr. Adam Feldman, Dr. Leo Cheng, and colleagues shows promising results for a non-invasive technique detecting metabolic signature between benign and cancerous prostate tissue.
A New Approach to Identifying Malignant Tumors in Tuberous Sclerosis Complex
Most of the renal lesions found in patients with tuberous sclerosis complex are benign, though occasionally, they can be cancerous. A research team at Massachusetts General Hospital is improving doctors' ability to differentiate between benign and malignant masses for the best patient care possible.
Multiparametric MRI For Prostate Cancer
A recent study suggests that multiparametric MRI can help with local staging of prostate cancer, improving treatment and prognosis in cancer patients.
COVID-19 Prevention in the Urological Community
Mass General urologist Adam Feldman, MD, MPH, discussed some key takeaways from Anthony S. Fauci, MD's address at the American Urologic Association's 2020 Live Virtual Experience, including the impact that COVID-19 has had on urologic care.
Active Surveillance of Prostate Cancer Is a Viable Option for Men Under 60
A large, two-institution retrospective study with prolonged follow-up showed that active surveillance is safe and effective for properly selected men younger than 60 years of age who have low-risk prostate cancer.
Comparative Effectiveness of Bladder-preserving Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer
According to decision analysis modeling by researchers at the Mass General Cancer Center, trimodality therapy with the goal of preserving the bladder is similar to radical cystectomy in terms of survival outcomes. However, trimodal therapy may provide a greater quality of life for patients with muscle-invasive bladder cancer.
Five Sessions to See at #AUA2019
The American Urological Association (AUA) is hosting its Annual Meeting in Chicago, IL from May 3-6, 2019. Specialists from the Massachusetts General Hospital Department of Urology will present on leading research and innovative treatment approaches. Mass General doctors will participate in over 20 different sessions covering the full spectrum of urologic care, including bladder, prostate, urologic oncology and more.
Molecular Testing Shows Promise for Predicting Outcomes of Patients with RCC
By combining clinicopathologic variables and a cell cycle gene assay, researchers have created a new way to predict survival of patients with localized renal cell carcinoma (RCC) who have undergone nephrectomy.
The Results of the First Penis Transplantation in U.S.
A man who survived penile cancer has become the first U.S. patient to undergo penis transplantation, with excellent early results.
Early Radiotherapy Best When Cancer Recurs After Radical Prostatectomy
The optimal timing of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy is controversial. Mass General researchers aim to clear up the controversy by reviewing patients who were treated in the modern era of PSA testing.
Multiparametric MRI/Ultrasound Fusion Biopsy Improves Prostate Cancer Detection
Active surveillance (AS) has become an accepted way to manage prostate cancer in men at lower risk. Multiparametric MRI can be used in conjunction with the standard transrectal ultrasound (TRUS)-guided biopsy to improve detection of clinically significant cancers.
Dr. Adam S. Feldman is a director of research and urologic oncologist in the Department of Urology at Massachusetts General Hospital, and is director of the Combined Harvard Urologic Oncology Fellowship. He completed his residency in urology in 2006 and subsequently completed his fellowship in urologic oncology in June 2008. Dr. Feldman focuses his clinical practice in the treatment of genitourinary cancers, using laparoscopic, endoscopic, and open techniques. He focuses his research interests on translational and clinical research in kidney, prostate and bladder cancers. He has received a Prostate Cancer Foundation Young Investigator Award for his work in novel biomarkers in prostate cancer and has been awarded a Physician Research Training Award by the Department of Defense. He is a co-PI on a Department of Defense Synergistic Idea Development Award on the development of conditionally reprogrammed cells in prostate cancer and is a co-investigator on an National Institutes of Health RO1 on metabolomic imaging in prostate cancer. In addition to his translational research work in genitourinary cancer biomarkers, he has worked to develop clinical databases in active surveillance in prostate cancer, use of imaging and fusion biopsy in prostate cancer, surgical and ablative treatments for renal cell carcinoma, and renal mass biopsy.